Source: American College of Rheumatology
Posted: November 13, 2006
Summary:
Early-stage clinical trials showed that reduced intensity hematopoietic stem cell transplantation (HSCT) in patients with systemic sclerosis (scleroderma) has proven safe and well tolerated, according new research. If results from the trial are valid over a long period of time, HSCT may become an acceptable therapeutic option for more individuals afflicted with severe forms of autoimmune disease.
No comments:
Post a Comment